# Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06192680/  
OnCo record `nct06192680` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of irinotecan (and liposomal irinotecan), capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by Harbin Medical University, not yet recruiting.

## Summary

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06192680 by Harbin Medical University, with a registry enrolment figure of 63 participants, started 2024-04-01 and due to reach its primary completion in 2025-11-30. Interventions recorded: Liposomal irinotecan; Capecitabine; Bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Progression free Survival. Colorectal eligibility wording from the registry: "* Histopathologically and/or cytologically confirmed unresectable metastatic colorectal adenocarcinoma, and patients failed or are intolerant to first-line treatment with oxaliplatin ± VEGF/EGFR". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06192680
- Phase: 2
- Setting: A Multicenter, Single-arm Study of Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
- Sponsor: Harbin Medical University
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT06192680: https://clinicaltrials.gov/study/NCT06192680

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06192680.json